PERPREVCID

Advancing Personalised Prevention and Early Intervention for Chronic Inflammatory Diseases

www.perprev-cid.eu

About PerPrev-CID

Millions of people across Europe live with **rheumatoid arthritis** (RA) and **inflammatory bowel disease** (IBD), two chronic inflammatory diseases (CIDs). While early detection and prevention are crucial, persistent **gaps in risk prediction** still limit timely and effective intervention.



PerPrev-CID tackles this challenge by developing innovative tools for **early molecular diagnosis and treatment** to predict early disease onset and relapse. With **people living with RA and IBD** central to their research, PerPrev-CID ensures the active involvement of those affected and supports informed decision-making for more **effective and personalised care.**

Duration

Jan 2025 - Dec 2029

Funding

13.5 Mio EU

15 Partners

8 countries

Goals

Identifying biomarkers and clinical features that predict disease progression and relapse

Assessing safe, digital tools for home-based health monitoring

Exploring the impact of nutrition on inflammation and disease outcomes

Building secure XAI-powered data analysis tools to support clinical decisions



Exploring implications of early risk detection and intervention alongside effective patient communication

The Scientific Approach

Molecular and clinical data analysis	In order to better understand disease trajectories, PerPrev-CID analyses blood and stool samples from people with RA, IBD, and at-risk groups.
Assessment of innovative health tools	The project evaluates apps and wearables for continuous home-based monitoring, while also using self-sampling methods for data collection.
Nutrition-based intervention	PerPrev-CID tests a gut-targeted nicotinamide (vitamin B3) intervention in early RA and IBD patients to reduce inflammation and restore microbiome balance.
Advanced Data Analysis Solutions	PerPrev-CID uses swarm learning and explainable AI to integrate health and molecular data for clinically relevant decision support and risk prediction.
Broader Impact Assessment	The project engages patients, healthcare professionals, and other stakeholders to explore the impact of risk-based intervention, and to develop effective, patient-centred communication.

The Expected Impact

SCIENTIFIC

Individualised risk stratification tools to support clinical decisions and shape future research and care for chronic inflammatory diseases.

TECHNOLOGICAL

Guidelines for innovative, secure digital health monitoring systems and enhanced trust in digitally supported tools and interventions.

ECONOMIC

Cost-efficient, low-threshold preventive interventions and potential innovative medical devices and health applications expected to support earlier diagnosis and reduce healthcare costs.

SOCIETAL

Enhancing quality of life and empowering people living with chronic inflammatory diseases, supporting self-management and promoting health literacy and equity.

Partners

IFCCA International Federation of Crohn's & Ulcerative Colitis Associations

LIÈGE université

VIB science meets life

CAU Christian-Albrechts-Universität zu Kiel

DZNE

EURICE

UK SH UNIVERSITÄTSKLINIKUM Schleswig-Holstein

WEIZMANN INSTITUTE OF SCIENCE

LITHUANIAN UNIVERSITY OF HEALTH SCIENCES

EngageMinds HUB Consumer, Food & Health Engagement Research Center

UNIVERSITÀ CATTOLICA del Sacro Cuore

KAUNO KLINIKOS

Radboud Universiteit

eular EUROPEAN ALLIANCE OF ASSOCIATIONS FOR RHEUMATOLOGY

UNIVERSITÉ DE GENÈVE

MANCHESTER 1824 The University of Manchester

Contact

PROJECT COORDINATION

Prof. Philip Rosenstiel
mail: Philip.Rosenstiel@uksh.de

PROJECT MANAGEMENT

Dr. Francesca Vaccaro
mail: f.vaccaro@eurice.eu

Website

LinkedIn

Funded by the European Union

Project funded by

Schweizerische Eidgenossenschaft
Confédération suisse
Confederazione Svizzera
Confederaziun svizra

Swiss Confederation

Federal Department of Economic Affairs, Education and Research EAER
State Secretariat for Education, Research and Innovation SERI

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HaDEA). Neither the European Union nor HaDEA can be held responsible for them.